'If continuous monitoring for low risk mothers doesn't reduce neonatal mortality and morbidity and does increase c/s rates than how can it be a good thing?'
-- where are you getting all that from? Would you rather have no monitoring and babies experiencing distress or worse? Monitoring in itself does not cause CSs. Monitoring provides indication to the medical staff that intervention may be necessary. How is that a bad thing? It is the information that monitoring provides that leads to the decisions that are made. Not all those decisions are the wrong ones, surely? CS rates are highest for obese mothers, who may need monitoring because of other conditions such as diabetes or heart problems. Labour is unpredictable even in mothers initially assessed as 'low risk'.
'Have I missed someone saying or implying that epidurals are highly dangerous?'
-- Yes, you did miss someone saying that epidurals are associated with a risk of uterine rupture and maternal and foetal death. It was an outrageous statement.
And yes, there are serious arguments on both sides of the debate on ABs. The serious cons have not been presented here on this thread, however, just a lot of hand wringing about MRSA and shock and horror that giving mothers routine ABs would even be contemplated, despite the fact that post op patients have routine ABs. If infection risk (for GBS for instance) is high and if neonatal fatalities result, then what's to be lost by routine ABS to women whose labour care involved exposure to infection and especially to those whose are at high risk for GBS -- preterm babies? (see link later in my post)
On the subject of GBS -- it can be screened for and treated before labour, during prenatal check ups. This screening is not routinely offered in the UK or in Finland, but it is elsewhere. Routine prenatal screening does not have any significant effect on occurrence between the US and UK though.
GBS does not only occur as a result of VE during labour. It affects certain groups more than others and is associated with diabetes across all groups. It is associated with preterm labour above all.
An excellent paper on GBS here -- 'early onset disease [occurring in days 0 - 7] may only be treatable intrapartum owing to very rapid progression.' So here it seems ABs may actually come in handy?
Here's an excerpt from the link:
'The mortality due to early onset GBS disease [0 - 7 days] has declined over time but remains higher than for late onset disease [7 - 89 days]. A large US multicentre study conducted in 1993?1998 reported a mortality rate of 4.7% for early onset disease (defined as positive culture from blood/cerebrospinal fluid), and 2.8% for late onset disease. The recent UK national surveillance study reported a mortality rate of 10.6% for early onset disease. This may be high relative to the US study because of delayed diagnosis in the absence of screening, or because less severely affected babies with GBS disease were not notified. In the US study, 2% of term babies with early onset GBS disease died, compared with 21% of babies born preterm. Overall, 17% of early onset GBS disease occurred in preterm babies, but they accounted for 68% of the deaths. UK studies have found that 83?100% of deaths due to GBS were in preterm babies.' So maybe it's not just the VE infection risk that gives babies GBS? Maybe there are other factors, and the protocols on VE intervals are not really helpful while more screening and more follow up care might be in preventing fatalities?
(And maybe the poster who argued the GBS and epidurals were linked should have checked their facts first? Especially 'UK studies have found that 83?100% of deaths due to GBS were in preterm babies.' It makes a difference in assessing the risk level of procedures, and drawing conclusions about epidurals, to point out that a very high proportion of deaths from GBS occurred in preterm babies. A huge difference.)
Here's part of the conclusion: 'there is moderate evidence that antibiotic prophylaxis is beneficial for GBS colonized women at high risk of adverse neonatal outcomes. Evidence is lacking on the effectiveness of antibiotic prophylaxis for the vast majority of women identified by GBS screening who have no other risk factors, and any benefits are likely to be small. Screening for GBS would not change management for women with prolonged preterm rupture of the membranes, as all should be treated, but screening may be beneficial for women at moderate risk of adverse outcomes, for example in preterm labour with intact membranes, in whom universal prophylaxis is not justified. The decline in GBS bacteraemia has been associated with a small increase in early onset E. coli bacteraemia in neonates which is associated with a higher mortality. However, it is not known whether changes in E. coli rates are related to antibiotic prophylaxis, or changes in the maternal or hospital acquired flora.'